ONCO Onconetix, Inc.

Nasdaq onconetix.gcs-web.com


$ 2.20 $ 0.02 (0.87 %)    

Monday, 17-Nov-2025 15:07:32 EST
QQQ $ 602.34 $ -5.20 (-0.85 %)
DIA $ 466.18 $ -5.48 (-1.16 %)
SPY $ 664.83 $ -6.26 (-0.93 %)
TLT $ 89.11 $ 0.22 (0.25 %)
GLD $ 370.86 $ -4.31 (-1.15 %)
$ 2.31
$ 2.30
$ 2.20 x 414
$ 2.27 x 31
$ 2.20 - $ 2.25
$ 2.20 - $ 179.35
16,786
na
3.25M
$ 2.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 06-12-2025 03-31-2025 10-Q
4 06-02-2025 12-31-2024 10-K
5 12-10-2024 09-30-2024 10-Q
6 08-29-2024 06-30-2024 10-Q
7 05-20-2024 03-31-2024 10-Q
8 04-11-2024 12-31-2023 10-K
9 11-17-2023 09-30-2023 10-Q
10 10-20-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Onconetix (NASDAQ:ONCO) reported quarterly losses of $(6.25) per share. This is a 97.49 percent increase over losses of $(249.0...

Core News & Articles

-SEC Filing

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused o...

Core News & Articles

Onconetix (NASDAQ:ONCO) reported quarterly losses of $(4.76) per share. This is a 99.78 percent increase over losses of $(2.19 ...

Core News & Articles

Pursuant to the Merger Agreement, Onconetix will acquire all of the issued and outstanding equity interests of Ocuvex and, in c...

Core News & Articles

Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION